P&G Ventures is looking for startup submissions on disruptive solutions in women's wellness. P&G is on a mission to help women (18+) optimize/enhance their health and wellness by (a) creating products that are designed specifically for women, (b) address gaps in her self-care and (c) offer meaningful difference in her life. We will start by addressing frequent, daily fatigue that negatively impacts her day, her capacity and ultimately her relationships.
DFactory is looking for startups aiming to expand in Europe and working on sensors, AI, blockchain, 3D printing, robotics, IoT, cybersecurity, and advanced manufacturing.
Opportunity for Startup Speakers for MIT ILP Digital Transformation Global Webinar Event to present their technology to hundreds of global corporate attendees as members of ILP, and to the MIT community as a whole. The digital future is here, and the threat of disruption looms large. In a rapidly expanding digital marketplace, legacy companies without a clear digital transformation strategy are being left behind. COVID-19 crisis has accelerated the transition to a digital future.
Epoch Foundation of Taiwan invite MIT-connected startups (in AI, Data Analytics, IoT, Digital Health, AR& VR, Robotics, Smart Transportation) to apply to their Global Startup Program, that since 2015, has invited 139 startups to discover business opportunities to explore global market and scale up ventures. Over 1/3 of the fellow startups had obtained business partners, investments or set up Taiwan branches through Epoch Foundation’s solid connections.
MIT Startup Exchange September 2025 Demo Day
September 17, 2025
Virtual Event
Epoch Foundation of Taipei Taiwan has invited MIT-connected startups to apply to their Global Startup Program. A number of MIT startups have participated in this program and found it very productive.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Looking for 8-10 startups to present their tech on May 5 at the 2022 MIT Efficient AI and Computing Technologies Conference.
MIT Startup Exchange is looking for 3-4 startup speakers to participate in a pre-recorded webcast on April 29 and a possible follow-up live event on May 4, both focused on work of the future.